Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 for Phelan-McDermid syndrome has completed all study visits.
Neuren Pharmaceuticals completes Phelan-McDermid syndrome Phase 2 trial
November 13, 2023 Australian BiotechLatest Video
New Stories
-
Moderna Announces the awardees for its 2024 Australia Fellowship Program
November 11, 2024 - - Latest News -
Mark Butler announces the creation of hybrid national program for RSV vaccine
November 11, 2024 - - Latest News -
Patients win when health ministers do what they are elected to do
November 11, 2024 - - Latest News -
Pharmac makes cancer therapy the 26th funded since budget boost
November 11, 2024 - - BioPharma -
Lundbeck announces its new leadership for Australia and NZ
November 8, 2024 - - Latest News -
ACCC will not oppose Sigma-Chemist Warehouse merger, subject to undertaking
November 8, 2024 - - Latest News -
AusBiotech and MTPConnect launch joint discussion paper on life science growth issues
November 8, 2024 - - Latest News